5685-69-8

Basic information

• Product Name: 1-METHYL-5-(TRIFLUOROMETHYL)-1H-INDAZOL-3-AMINE
• Synonyms: 1-METHYL-5-TRIFLUOROMETHYL-3-INDAZOLYLAMINE;1-METHYL-5-(TRIFLUOROMETHYL)-1H-INDAZOL-3-AMINE;3-Amino-1-methyl-5-(trifluoromethyl)-1H-indazole, 95%;1-Methyl-5-trifluoroMethyl-1H-indazol-3-ylaMine;1-Methyl-5-(trifluoromethyl)indazol-3-amine
• CAS NO: 5685-69-8
• Molecular Formula: C₉H₈F₃N₃
• Molecular Weight: 215.18
• Product Categories: Amines;Fused Ring Systems
• Mol File: 5685-69-8.mol
• Article Data: 6

Chemical Properties

• Appearance: White to yellow/Crystalline Powder
• CAS DataBase Reference: 1-METHYL-5-(TRIFLUOROMETHYL)-1H-INDAZOL-3-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-METHYL-5-(TRIFLUOROMETHYL)-1H-INDAZOL-3-AMINE(5685-69-8)
• EPA Substance Registry System: 1-METHYL-5-(TRIFLUOROMETHYL)-1H-INDAZOL-3-AMINE(5685-69-8)

Safety Data

• Hazard Codes: T
• Statements: 36/37/38-36-25
• Safety Statements: 26-36/37/39-45
• Hazardous Substances Data: 5685-69-8(Hazardous Substances Data)

Usage

Class

Indazoles

Explanation

Heterocyclic compounds containing a five-membered ring with three carbon atoms and two nitrogen atoms.

Explanation

TRKs are kinase enzymes involved in promoting cell growth and survival.

Explanation

The compound's ability to target TRKs makes it a potential candidate for the development of new cancer therapies.

Explanation

The presence of the trifluoromethyl group improves the compound's stability and its behavior within the body, making it more effective as a pharmaceutical agent.

Explanation

Due to its ability to target TRKs and its enhanced properties, 1-Methyl-5-(trifluoromethyl)-1H-indazol-3-amine has the potential to be a significant agent in the future of cancer treatment and therapy development.

Function

Potent and selective inhibitor of TRKs (tropomyosin receptor kinases)

Preclinical Studies

Treatment of various types of cancers

Examples

Colorectal, gastric cancer, and neuroblastoma

Trifluoromethyl group

Enhanced metabolic stability and pharmacokinetic properties

Potential

Important pharmaceutical agent

Upstream product

• 328-87-0 2-chloro-5-(trifluoromethyl)benzonitrile 
• 60-34-4 methylhydrazine 
• 2250-53-5 3-amino-5-(trifluoromethyl)-1H-indazole 
• 943247-23-2 3-(2,5-dimethyl-1H-pyrrol-1-yl)-1-methyl-5-(trifluoromethyl)-1H-indazole 
• 4088-84-0 2-fluoro-5-trifluoromethyl-benzonitrile 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS FOR THE CONTROL OF INVERTEBRATE PESTS

The invention relates to compounds of formula (I) wherein the variables have the meanings as defined in the specification, to compositions comprising them, to active compound combinations comprising them, and to their use for protecting growing plants and

CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2

The present invention comprises compounds of Formula (I). wherein: R1, R2, X, and Z are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

Cyclic derivatives as modulators of chemokine receptor activity

The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of rheumatoid arthritis, multiple sclerosis, atherosclerosis, asthma, restinosis, organ transplantation, and